spacer
home > ebr > autumn 2019 > the next-generation purification of monoclonal antibodies
PUBLICATIONS
European Biopharmaceutical Review

The Next-Generation Purification of Monoclonal Antibodies




There is unprecedented pressure on the biopharmaceutical industry to improve the performance of monoclonal antibody (mAb) development and manufacturing processes. There are several factors essential to addressing this challenge, including flexibility (in which product changeover time is reduced), quality (as defined by increased robustness and reliability), speed (in which production and product release are accelerated), and cost reductions in manufacturing and capital expenditure.

Improvements in processes and productivity can enable smaller and simpler facilities and lower costs, leading to several advantages, including the ability to:

• Improve competitiveness and long-term sustainability
• Enable business models for new biologics and novel therapies
• Supply developing countries with affordable biologics
• Reach emerging markets profitably

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Skarja is the Head of Membrane Chromatography R&D at Merck. He has 20 years of experience leading dynamic R&D teams in a variety of life sciences sectors, including biopharma, medical device, and cell and gene therapy. Gary holds over 20 patents related to novel polymers, devices, and processes for life sciences applications. He has Bachelor’s and Master’s Degrees in Chemical Engineering from McMaster University, Canada, and a PhD in Chemical Engineering from the University of Toronto, Canada.
spacer
Gary Skarja
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement